{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000049","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.047500+00:00","generated_at":"2026-05-21T09:58:23.503663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AEON Biopharma appoints new CEO, advances ABP-450 biosimilar path, reports $10.4M cash","bullets":["Rob Bancroft appointed President and CEO effective April 29, 2025; also joins Board. Former CEO Marc Forth remains on Board.","Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference; plans BPD Type 2a meeting with FDA in H2 2025.","Cash and equivalents of $10.4M at March 31, 2025; expected to fund operations through Q4 2025 and planned FDA meeting.","NYSE American accepted compliance plan; granted until August 3, 2026 to regain continued listing standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000049","json":"https://secwatch.observer/filing/0001837607-25-000049.json","markdown":"https://secwatch.observer/filing/0001837607-25-000049.md","text":"https://secwatch.observer/filing/0001837607-25-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000049/0001837607-25-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000049/aeon-20250514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:58:23.503663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}